Lite Strategy, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Lite Strategy, Inc. (LITS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $22.00 thousand for the 12-month period ending 2024-06-30, per its 10-K filed 2025-09-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-09-26
- Lite Strategy, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $22.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|
| 2024-06-30 | $22.00K 10-K · filed 2025-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |